News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ulthera Appoints Greg Waller as Chief Financial Officer


12/6/2011 11:10:40 AM

MESA, Ariz., Dec. 6, 2011 /PRNewswire/ -- Ulthera, Inc. a global, commercial-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology today announced that it has named Greg Waller as Chief Financial Officer (CFO), a newly created position at Ulthera.

(Photo: http://photos.prnewswire.com/prnh/20111206/NY17456-a)

(Photo: http://photos.prnewswire.com/prnh/20111206/NY17456LOGO-b)

"Greg's results-oriented skillset will play a vital role in further enhancing our sound corporate infrastructure as more and more cosmetic physicians in the U.S. and internationally adopt our device to help meet the ever-growing consumer demand for safe and effective non-invasive procedures," said Matthew Likens, president and CEO of Ulthera. "I am confident that Greg will provide steadfast leadership to ensure a strong financial future for our growing company, especially as we tap the potential of our platform technology."

Waller's three-and-a-half decades of experience showcases a solid track record of strategic financial growth for both privately held and publically traded companies. Most recently, Waller served as CFO of Universal Building Products, a manufacturer of concrete construction accessories. Prior to that, he held several leadership positions at Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products. During his 25-year tenure with Sybron, he was instrumental in the IPO of the company and in more than 30 company acquisitions worldwide. He also played a pivotal role in supporting the growth of the company from 100 to more than 4,000 employees and from $10 million to more than $750 million in sales.

Waller currently serves as a board member and audit committee chairman for Endologix, Inc. and as a board member for Sunshine Heart, Inc. Additionally, he previously served as board member and audit committee chairman for Alsius, Inc., Biolase, Inc., Cardiogenesis Inc., Clarient, Inc. and SenoRx, Inc., all publicly traded companies.

"Although a young company, the technology achievements, market penetration and clinical respect that Ulthera has garnered in such a short period of time is not only impressive and significant; it is an auspicious indicator of what's to come," stated Waller. "I am honored to be part of such a promising company where medical innovation is highly encouraged, and consistency, safety and efficacy are at the heart of operating principals."

About Ulthera

Ulthera®, Inc. is a global, commercial-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® the procedure enabled by the System is a non-invasive face and neck treatment to achieve a brow lift. Founded in 2004 and based in Mesa, Ariz., Ulthera is a privately held company backed by top tier venture capital firms, New Enterprise Associates and Apposite Capital. For more information, visit www.ulthera.com.

SOURCE Ulthera


Read at BioSpace.com

comments powered by Disqus
Ulthera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES